Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Hematuria is a medical condition that is indicated by the presence of blood in the urine under normal circumstances. The urine does not contain red blood cells, which can lead to a serious problem that can also cause kidney stones, urinary tract infections, and other hereditary diseases. The high prevalence of hematuria-related indications and increasing awareness of treatment options and improved healthcare spending are driving the market. In addition, the increasing scope for related treatments is expected to provide significant growth opportunities for hematuria treatment market participants to expand their customer base, particularly in developing countries.
The factors driving the growth of the market are the incidence of hematuria with increasing age and people over 35 are more likely to develop symptoms of hematuria. The geriatric population is expected to expand the patient pool, which in turn is expected to propel the hematuria treatments market during the forecast period. The high prevalence of diseases such as urinary tract infections and kidney stones, increased incidence of hematuria in adults, extensive research and development activities, the advent of high throughput screening (HTS) for drug discovery, and FDA drug approvals are the most important factors driving the growth of hematuria treatment market in the forecast period.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Europe hematuria treatment market. In addition, complete analysis of changes on the Europe hematuria treatment market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The Europe region witnessed exponential growth in the number of COVID-19 cases. The hematuria cases are reported to have a greater prevalence among COVID-19 patients which positively impacted the growth of hematuria treatment market in the region.
The hematuria treatment market comprises of different market segment like type, indication, treatment, end user and country.
The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Common urological causes of hematuria include urinary tract infection and ureteric and renal stones. Macroscopic hematuria is evident immediately with red discoloration of the urine whereas in microscopic hematuria there is no visual evidence of the presence of blood unless the urine is viewed under a microscope. In case of idiopathic hematuria there is no specific reason for the presence of blood in the urine also the idiopathic hematuria can be hereditary and so it is also called as familial idiopathic hematuria and when there is not a family history of kidney failure and other medical tests reports are negative in such cases no specific treatment is required. The jogger’s hematuria occurs as a result of recurrent damage to the bladder during activities such as jogging and long-distance running.
The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. Urinary tract infections are commonly caused by microorganisms, usually bacteria that enter the urethra and bladder causing inflammation and infection. The UTI infection most commonly happens in the urethra and bladder but the bacteria can travel up the ureters and infect the kidneys. High levels of calcium in the urine can cause kidney stone also in people with the family history of kidney stones are more susceptible to kidney stones that gradually causes hematuria.
The hematuria treatment market includes different treatments such as drugs, therapies. Depending upon the condition causing hematuria treatment might involve taking antibiotics to clear a urinary tract infection. Also some medication can help to shrink an enlarged prostate or having shock wave therapy to break up bladder or kidney stone whereas in some cases no treatment is necessary to treat the hematuria. Drugs like alfuzosin is used to treat an enlarged prostate by relaxing the muscles in the prostate and bladder neck and help to urinate easily. Also ciprofloxacin is a fluoroquinolone antibiotic prescribed for certain types of bacterial infections such as pneumonia, urinary tract infections.
The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The hematuria is caused due to the urinary tract infection and is treated with antibiotics. Also after treating with the antibiotics doctors recommends doing multiple urine tests to make sure the infection is gone. In case of severe infection with the doctors consultation imagining tests such as tomography or magnetic resonance imaging scan. Also to evaluate the cause of urinary bleeding cystoscopy is done. Also for accurate diagnosis and treatment of the disease hospitals equipped with tools using the advance technology plays a crucial role in the treatment of the hematuria treatment contributing to the growth of hematuria treatment market in the forecast period.
The Europe hematuria treatment market is studied for the following countries like France, Germany, Italy, Spain and UK. The market in the region is driven by increase in demand for new therapeutics, extensive research in the field of urinary tract infection care, well-established healthcare facilities and geographical expansion of market players are some of the factors propelling the growth of the market. The increasing government funding and rapid advancement in the healthcare sector contributes to the growth of the market in the region.
The key players in hematuria treatment market are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH and The Medicines Company among others.
September 2021: AstraZeneca collaborated with VaxEquity for the discovery, development, and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
September 2021: Merck announced its definitive agreement to acquire Acceleron. Following the purchase of shares in the tender offer, Acceleron will become a subsidiary of Merck.
August 2021: Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for anticancer treatments.
June 2021: Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
July 2021: GlaxoSmithKline plc. and Alector, announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
The report analyses the hematuria treatment market based on by type, indication, treatment, end user and country. The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Common urological causes of hematuria include urinary tract infection and ureteric and renal stones. The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. The hematuria treatment market includes different treatments such as drugs, therapies. Depending upon the condition causing hematuria treatment might involve taking antibiotics to clear a urinary tract infection. Also some medication can help to shrink an enlarged prostate or having shock wave therapy to break up bladder or kidney stone. The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The hematuria is caused due to the urinary tract infection and is treated with antibiotics. Also after treating with the antibiotics doctors recommends doing multiple urine tests to make sure the infection is gone. The Europe hematuria treatment market is studied for the following countries like France, Germany, Italy, Spain and UK.
Why to buy this report
